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Kati Kivelä1, Mika Laine2, Kirsi Lauerma4 & Johanna Kuusisto5
this manuscript has not been published before and is not currently being considered for publication 
elsewhere. Increased septal convexity of left ventricle has been described in subjects with hypertrophic 
cardiomyopathy (HCM) -causing mutations without left ventricular hypertrophy (LVH). our objective 
was to study septal convexity by cardiac magnetic resonance (CMR) in subjects with the Finnish founder 
mutation Q1016X in the myosin-binding protein C gene (MYBPC3). septal convexity was measured 
in end-diastolic 4-chamber CMR image in 67 study subjects (47 subjects with the MYBPC3-Q1061X 
mutation and 20 healthy relatives without the mutation). Septal convexity was significantly increased 
in subjects with the MYBPC3-Q1061X mutation and LVH (n = 32) compared to controls (11.4 ± 4.3 
vs 2.7 ± 3.2 mm, P < 0.001). In mutation carriers without LVH, there was a trend for increased septal 
convexity compared to controls (4.9 ± 2.5 vs 2.7 ± 3.2 mm, P = 0.074). When indexed for BSA, septal 
convexity in mutation carriers without LVH was 2.8 ± 1.4 mm/m2 and 1.5 ± 1.6 mm/m2 in controls 
(P = 0.036). In all mutation carriers, septal convexity correlated significantly with body surface area, 
age, maximal LV wall thickness, LV mass, and late gadolinium enhancement. subjects with the 
MYBPC3–Q10961X mutation have increased septal convexity irrespective of the presence of LVH. 
Septal convexity appears to reflect septal remodeling, and could be useful in recognizing LVH negative 
mutation carriers.
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disease and one of the most 
common causes of sudden cardiac death in the young1. HCM is caused by autosomal dominant mutations in 
genes encoding mainly sarcomeric proteins. More than 1400 mutations causing HCM have been identified in 
over 13 genes2. In familial HCM, there is a 50% chance that the first-degree relative will inherit the gene mutation 
leading to the disease. HCM is a heterogenous disease with variable clinical phenotype even in patients carrying 
the same causal mutation3. Clinical presentation may vary from asymptomatic to arrhythmia, heart failure and 
sudden death. Clinical manifestations of HCM usually develop during adolescence but myosin-binding protein 
C gene (MYBPC3) mutation carriers often have no LVH or develop LVH later in life4–6.
More than 40% of the mutations causing HCM are found in the MYBPC3 gene7. The founder mutation 
Q1061X in MYBPC3 (MYBPC3-Q1061X) is the most common single mutation causing HCM in Finland and 
is found in about 11% of Finnish HCM cases5,8,9. To our knowledge, this mutation is extremely rare outside 
Finland, with one reported mutation in non-Finnish populations according to the Genome Aggregation Database 
(gnomAD). This autosomal dominant mutation has a relatively low penetrance and often, but not always, mild 
phenotype6,8. Of the subjects with the Finnish founder mutation MYBPC3-Q1016X, 20 to 30% do not have LVH 
and are considered phenotype negative mutation carriers6,8,10.
Hypertrophic cardiomyopathy is characterized by asymmetric LV hypertrophy, most often located in the LV 
anterior septum or free wall. Of HCM patients with reverse septal curvature on echocardiography, nearly 80% 
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have a positive genetic test for myofilament HCM, contrasting those with sigmoidal septal morphology, who have 
positive genetic test in fewer than 10% of cases11. Recently, CMR derived septal convexity into the LV has been 
suggested to be an additional, previously undescribed feature of subclinical HCM12. Compared to controls, abnor-
mal convexity was significantly increased in phenotype negative carriers of HCM-causing mutations in multiple 
sarcomere genes. To our knowledge, there are no other studies regarding this topic. Therefore, the purpose of 
our study was to further investigate septal convexity by CMR in subjects carrying the single MYBPC3-Q1016X 
mutation and their healthy relatives.
Methods
study population. All available subjects with the MYBPC3-Q1061X mutation and their healthy relatives 
from Kuopio and Helsinki University Hospital areas were prospectively recruited. Altogether, 74 adult subjects 
representing 25 families with the Finnish founder mutation MYBPC3-Q1061X were screened. The Genome 
Center of the University of Eastern Finland performed all the genetic studies as previously described8. All index 
patients of the present study were screened for 59 cardiomyopathy associated genes, and no other pathogenic or 
likely pathogenic mutations in addition to MYBPC3-Q1061X were found in any of the patients9. Seven subjects 
had implanted pacemaker precluding CMR imaging and were excluded from the study. The final study popula-
tion consisted of 67 individuals (47 with the MYBPC3-Q1061X mutation with or without LVH, and 20 healthy 
relatives without the MYBPC3-Q1061X mutation).
The G+/LVH+ group consisted of 32 subjects with the MYBPC3-Q1061X mutation and no other cause for 
significant hypertrophy (LV maximal wall thickness [LVMWT] ≥ 13 mm in CMR), and 15 subjects with the same 
mutation but no hypertrophy (LVMWT < 13 mm in CMR) consisted the G+/LVH− group.
The study conforms to the principles outlined in the Declaration of Helsinki and the ethics committees at 
the Kuopio and Helsinki University Hospitals approved the study protocol. All subjects gave informed written 
consent.
echocardiography. All subjects underwent echocardiographic studies which were carried out by experi-
enced cardiologists (J.K., P.J., M.J.) with GE Vivid 7 ultrasound equipment (GE Vingmed, Norway). Conventional 
measurements were performed according to AHA/ASE guidelines. A resting gradient >30 mmHg through the 
left ventricular outflow tract (LVOT) was considered significant13.
CMR. CMR images were obtained with the same study protocol in both participating hospitals (Kuopio and 
Helsinki University Hospitals) as described previously14. Delayed-enhancement images were obtained 10 min-
utes after injection of gadoterate meglumine (Dotarem®) 0.2 mmol/kg contrast agent using segmented trueFISP 
IR sequence in short axis orientation and in two long axis orientations (4- and 2-chamber views). The imaging 
parameters were 700 msec temporal resolution, 1.08 msec echo time, flip angle 50°, acquisition matrix 192 × 144 
and 340 × 340 field of view. Slice thickness was 8 mm and intersection gap 20%. Inversion time was optimized to 
null the signal intensity of normal myocardium.
Image Analyses. All of the anatomical measurements on CMR images were performed by using Sectra IDS7 
workstation. Image analysis was performed by experienced analyzers with no data of the study subjects’ clinical 
or genetic findings. Septal convexity into the LV was measured in end-diastolic 4-chamber images as the maximal 
distance between LV septal endocardial border and a line connecting septal mid-wall points at the level of tricus-
pid valve insertion and at the level of apical right ventricular insertion on the LV as described previously12 [Fig. 1]. 
Figure 1. Measurement of septal convexity in end-diastolic 4-chamber CMR image. The red line is a reference 
line between the mid-wall at the level of tricuspid valve and the insertion point of the right ventricle into the left 
ventricle at the apex. The yellow line is the measured septal convexity. This particular subject has the measured 
septal convexity of 9 mm and left ventricular maximal wall thickness of 12 mm.
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M.T. (with 5 years experience in CMR) performed all septal convexity measurements. All the other anatomical 
measurements of the CMR images were performed as described previously14. Areas of late gadolinium enhance-
ment (LGE) were traced by QMass® late-enhancement analysis software (QMass® 7.2, Medis Medical Imaging 
Systems, Netherlands) in short axis images and quantified segmentally as absolute and relative mass in a standard 
16-segment model. A threshold of +6 SD was used for detection of LGE15.
Measurement repeatability was evaluated by measuring septal convexity twice in 20 randomly selected sub-
jects. M.T. tested intraobserver variability by re-measuring septal convexity more than 6 months after the initial 
measurement. Interobserver variability was calculated from the same 20 measurements by another radiologist 
(K.K.).
Statistical Analyses. Data is presented as mean ± standard deviation. Many of the variables had skewed dis-
tribution and were compared with Kruskal-Wallis one-way analysis of variance and independent samples with the 
Mann-Whitney U test. Receiver operating characteristic (ROC) curve was constructed to test the ability of septal 
convexity to differentiate between mutation carriers without LVH and control subjects. Paired samples T-test and 
Pearson correlation coefficient was used in repeatability testing. All statistical analyses were performed with IBM 
SPSS Statistics V22.0. and were considered significant with a P < 0.05.
Results
Characteristics of the study groups. Table 1 shows baseline, echocardiographic and CMR characteristics 
of the three study groups. G+/LVH− subjects were younger and had lower BSA compared to other groups. There 
were more males were in the G+/LVH− group compared to other groups. G+/LVH− subjects were all in NYHA 
1 class14. They did not have cardiac symptoms or clinical findings (data not shown).
No septal interventions (myectomy or ablation) had been performed in any of the study subjects. There was 
one subject with significant LVOT obstruction (gradient >30 mmHg on echocardiography) in the G+/LVH+ 
group. However, the mean LVOT gradients did not differ significantly between the study groups.
CMR derived LVMWT and left ventricular mass index (LVMI) differed between study groups, as expected. 
Ventricular volume indices (LVEDVI and LVESVI) and LVEF did not differ between study groups. G+/LVH+ 
subjects had mostly moderate hypertrophy (LVMWT 22.1 ± 5.7 mm) located mainly in septum (72%) or anterior 
wall (25%). True apical hypertrophy was not found. No significant difference was found in LVMWT between 
G+/LVH− subjects and controls (9.5 ± 1.6 vs 9.6 ± 1.7 mm, P = 0.882). LVMI was significantly increased in G+/
LVH+ group compared to other groups (68 ± 21 g/m2, P < 0.001), but not in G+/LVH− subjects compared to 
controls (49 ± 13 vs 45 ± 9 g/m2, P = 0.438). In the G+/LVH+ group, 23 subjects had LGE, as only one in the G+/
LVH− group had LGE. In the subjects with LGE, the mean amount of LGE was 18 ± 12% of the LV myocardium 
(range 1–45%).
MYBPC control MYBPC G+/LVH− MYBPC G+/LVH+ P
Patients, n 20 15 32
Age, y 46 ± 17 33 ± 16* 50 ± 11 0.007
Men, n 5 (25%) 3 (20%) 20 (63%)* <0.001
BSA, m² 1.87 ± 0.28 1.75 ± 0.18* 1.94 ± 0.20 0.004
Height, cm 169 ± 10 167 ± 6 174 ± 9 0.04
Weight, kg 76 ± 24 68 ± 13 81 ± 14 0.005
BMI 27 ± 8 24 ± 4 27 ± 4 0.129
NYHA, n
I — — 28 (88%)
II — — 4 (13%)
LVOT gradient, mmHg 7.1 ± 2.9 5.7 ± 1.8 8.5 ± 11.4 0.42
LVMWT, mm 9.6 ± 1.7 9.5 ± 1.6 22.1 ± 5.7* <0.001
LVMI, g/m2 45 ± 9 49 ± 13 68 ± 21* <0.001
LVEDVI, ml/m2 78 ± 13 78 ± 15 74 ± 14 0.55
LVESVI, ml/m2 32 ± 10 30 ± 7 28 ± 10 0.13
LVEF, % 60 ± 8 62 ± 5 63 ± 9 0.12
LGE,n — 1 23* <0.001
SC, mm 2.7 ± 3.2 4.9 ± 2.5 11.4 ± 4.3* <0.001
Table 1. Baseline, echocardiographic and CMR characteristics. MYBPC-control = healthy controls 
without MYBPC3 mutation, MYBPC G+/LVH− = MYBPC3 mutation carriers without LVH, MYBPC G+/
LVH+ = MYBPC3 mutation carriers with LVH in CMR, BSA = body surface area, BMI = body mass index, 
NYHA = New York Heart Association functional class, LVOT gradient = left ventricular outflow tract gradient, 
LVMWT = left ventricular maximal wall thickness, LVMI = left ventricular mass index, LVEDVI = left 
ventricular end-diastolic volume index, LVESVI = left ventricular end-systolic volume index, LVEF = left 
ventricular ejection fraction, LGE = late gadolinium enhancement, SC = septal convexity into the left ventricle. 
*Significance P < 0.05 between MYBPC groups and controls.
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septal convexity into the LV. Septal convexity measurement was feasible in all study subjects. Table 1 and 
Fig. 2a,b show the results of septal convexity measurements in the three study groups. There was a significant 
difference in septal convexity between G+/LVH+ group and controls (11.4 ± 4.3 vs 2.7 ± 3.2 mm, P < 0.001), 
and between G+/LVH+ and G+/LVH− groups, respectively (11.4 ± 4.3 vs 4.9 ± 2.5, P < 0.001) (Table 1 and 
Fig. 2a) (Fig. 3). The difference between the G+/LVH− group and the controls was not quite significant (4.9 ± 2.5 
vs 2.7 ± 3.2 mm, P = 0.074; CI 95% 3.5–6.3 mm vs 1.2–4.2 mm). However, when indexed for BSA, the difference 
Figure 2. (a) Septal convexity into the LV in study groups. There is a significant difference between the G+/
LVH+ group and other groups. (b) Septal convexity into the LV indexed for BSA. There is a significant 
difference between the G+/LVH+ group and other groups. Also the difference between G+/LVH− and control 
group is significant.
Figure 3. Ventricular end-diastolic CMR images in 4-chamber orientation (a) a control subject, (b) a subject 
with MYBPC3-Q1061X mutation but no LVH and (c) a subject with MYBPC3-Q1061X mutation and LVH.
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in SC values between all groups, including the G+/LVH− group and the control group, was statistically sig-
nificant (2.8 ± 1.4 vs 1.5 ± 1.6 mm/m2, P = 0.036). Also the difference between G+/LVH+ group and controls 
(5.9 ± 2.2 vs 1.5 ± 1.6 mm/m2, P < 0.001) and G+/LVH+ group and G+/LVH− group (5.9 ± 2.2 vs 2.8 ± 1.4 mm/
m2, P < 0.001) was significant (Fig. 2b).
In MYBPC3 mutation carriers, increased septal convexity correlated significantly with BSA (r = 0.332, 
P = 0.006), age (r = 0.508, P < 0.001), LVMWT (r = 0.742 P < 0.001), LVM (r = 0.590, P < 0.001) and LGE 
(r = 0.683, P < 0.001). There was no correlation between septal convexity and LVEF (r = −0.083, P = 0.578) or LV 
volumes (LVEDV, r = 0.131, P = 0.379 and LVESV, r = −0.111, P = 0.459).
Figure 4 shows receiver operating characteristic (ROC) curve of septal convexity as a predictor of mutation 
presence but no LVH. Area under the curve (AUC) was 0.68 and a cutoff value of 3.85 mm performed best with 
sensitivity 67% and specificity 65%. When indexed for BSA, AUC was 0.71 and a cutoff value 2.34 mm/m2 per-
formed best with sensitivity 60% and specificity 75%.
Figure 4. (a) ROC curve for septal convexity into the LV to differentiate between MYBPC3-Q1061X mutation 
carriers without LVH and controls. AUC is 0.68 (95% Confidence Interval (CI) 0.5–0.86). (b) ROC curve for 
BSA indexed septal convexity into the LV to differentiate between MYBPC3-Q1061X mutation carriers without 
LVH and controls. AUC is 0.71 (95% Confidence Interval (CI) 0.54–0.89).
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Reproducibility of septal convexity measurements. There was no significant difference between 
the first and second measurement of the septal convexity in intraobserver analysis measurements (10.3 ± 4.6 
vs 10.5 ± 4.7 mm, P = 0.66) and the correlation between measurements was excellent (r = 0.961, P < 0.001). 
Interobserver measurements showed no significant difference between measurements (10.3 ± 4.6 vs 
10.4 ± 4.2 mm, P = 0.65) and an excellent correlation between measurements (r = 0.973, P < 0.001).
Discussion
Subjects with the MYBPC3–Q10961X mutation have increased left ventricular septal convexity irrespective of the 
presence of LVH. In mutation carriers, septal convexity correlates with BSA, age and CMR derived LV maximal 
thickness, mass and late gadolinium enhancement.
To our knowledge, there is only one previous study on CMR derived LV septal convexity in HCM-causing 
mutation carriers11. In aforementioned study, abnormal convexity was significantly increased in 36 phenotype 
negative carriers of HCM-causing mutations in multiple sarcomere genes, including MYBPC3, beta-myosin 
heavy chain (MYH7), troponin t (TNNT2), troponin I (TNNI3), myosin regulatory light chain (MYL2), myosin 
essential light chain (MYL3), tropomyosin (TPM1), and cardiac alpha-actin (ACTC1)11. In the present study, all 
mutation carriers had a single founder mutation of MYBPC3, and the septal convexity in LVH negative mutation 
carriers differed significantly from that of healthy controls only after indexing for BSA. In the present study, 
LV septal convexity with a cut point of >3.85 mm (AUC 68%, sensitivity 67% and specificity 65%) predicted 
MYBPC3-Q1061X mutation presence without LVH. Correspondingly, in the previous study, septal convexity cut 
point of >3.55 mm had best balance between sensitivity (77%) and specificity (89%) to predict mutation presence 
without LVH11. When indexed for BSA, LV septal convexity sensitivity was somewhat lower but specificity was 
higher (AUC 0.71 with cut point of >2.34 m/m2, sensitivity 60% and specificity 75%).
We found that septal convexity correlates significantly with BSA, age, and CMR derived LV maximal thick-
ness, mass and late gadolinium enhancement in subjects with MYBPC3-Q1061X. To our knowledge, there are no 
previous correlation analyses on the topic.
Hypertrophic cardiomyopathy is characterized by asymmetric LV hypertrophy, most often located in the LV 
anterior septum or free wall. Bulging of septum, resulting in septal convexity, may precede increase in maximal 
wall thickness in the development of HCM, as suggested by the previous and present study. LV septal convexity 
correlated with BSA, age, LVMWT, LVM, and LGE in subjects with MYBPC3-Q1061X in our study. We propose 
that septal convexity reflects early-onset, body size and age -related septal remodeling in carriers of HCM-causing 
sarcomere mutations.
Measuring LV septal convexity in CMR is simple and highly reproducible, as shown by the present and the 
previous study. Septal convexity is measured in 4-chamber CMR images, which are usually included in CMR 
protocols used in clinical setting, and are therefore, readily available for measurement in subjects with HCM 
or LVH of unknown origin, and suspect carriers of HCM-causing mutations. Septal convexity, like most CMR 
parameters, correlates significantly with BSA. Consequently, indexing for BSA probably increases utility of septal 
convexity as shown by our study.
Our study population is relatively small. On the other hand, it is a cohort with a single HCM-causing mutation 
and, consequently, bias caused by multiple diverse mutations is avoided. MYBPC3 mutations are the most com-
mon cause of HCM accounting for about 40% of all HCM cases globally. Furthermore, MYBPC3-Q1016X might 
be regarded to represent most MYBPC3 mutations, as like two thirds of all MYBPC3 mutations, it leads to the 
production of a truncated protein and, consequently, to haploinsufficiency, characterized by absence of mutant 
protein in myocytes16–18.
Non-indexed measurements showed a non-significant trend for septal convexity abnormality in mutation 
carriers without LVH compared to control subjects. However, the G+/LVH− subjects in the present study were 
younger and had a smaller BSA than control subjects, and both age and BSA correlated with septal convexity. 
BSA indexed values showed significant difference in septal convexity between G+/LVH− subjects and controls.
Even in the present era of targeted sequencing of large cardiomyopathy gene panels, the pathogenic or likely 
pathogenic mutation is found only in about 60% of HCM cases9. Age-related increase in penetrance of HCM 
implies that a proportion of clinically unaffected mutation carriers will develop overt cardiomyopathy later in 
life, and thus, precautionary long-term evaluation of normal healthy mutation carriers and relatives of patients 
without disease-causing mutation is recommended19. Hence, we need imaging methods to identify the relatives 
at risk of developing HCM. Imaging is especially important in families with mutations which may represent 
LVH in the middle-ages, as in the case of MYBPC3 mutations2,20. One previous study has suggested that CMR 
derived septal convexity is a potential tool in finding phenotype negative HCM -causing mutation carriers12. In 
the present study, we showed that CMR derived septal convexity is significantly increased in carriers of the single 
mutation in MYBPC3. Septal convexity was related to BSA, and particularly if indexed for BSA, differed between 
LVH-negative mutation carriers and controls. Consequently, CMR derived septal convexity may have value in 
the evaluation of family members of patients with HCM to find relatives at risk of developing clinical HCM, par-
ticularly when genetic testing in the proband is not available or is negative. As septal convexity correlated with 
age and LVH and myocardial fibrosis in the whole mutation carrier group, it might be useful measure of severity 
of the disease also in the follow-up of patients with overt HCM. However, as septal derived convexity has been 
investigated only in two small studies, its utility requires further large-scale studies.
As a conclusion, subjects with the MYBPC3–Q10961X mutation have increased septal convexity irrespective 
of the presence of LVH. Septal convexity appears to reflect early onset, body size and age-related septal remode-
ling and could be useful in identifying phenotype-negative mutation carriers.
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ethical approval and informed consent. Institutional Review Board approval was obtained for the study 
and study methods were carried out in accordance with the relevant guidelines and regulations. Written informed 
consent was obtained from all subjects in this study.
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